• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增量成本效果比的区间估计问题。

Problems with interval estimates of the incremental cost-effectiveness ratio.

作者信息

Heitjan D F, Moskowitz A J, Whang W

机构信息

Division of Biostatistics, International Center for Health Outcomes and Innovation Research, Columbia University, New York, New York, USA.

出版信息

Med Decis Making. 1999 Jan-Mar;19(1):9-15. doi: 10.1177/0272989X9901900102.

DOI:10.1177/0272989X9901900102
PMID:9917015
Abstract

The defining feature of a confidence interval is that it has a fixed minimum probability of covering the true value of the parameter being estimated, whatever the value of the parameter. The authors demonstrate by simulation that some recently proposed methods for interval estimation of the incremental cost-effectiveness ratio (ICER) either do not satisfy this definition or have other problems that limit their usefulness in applications. The problems are most prominent when the ICER is large and the true effectiveness difference is small relative to its standard error. A modification of the percentile bootstrap confidence interval that involves a reordering of the sample space provides a partial solution of the problem.

摘要

置信区间的定义特征是,无论参数的值如何,它都有一个固定的最小概率覆盖被估计参数的真实值。作者通过模拟证明,一些最近提出的增量成本效益比(ICER)区间估计方法要么不满足这个定义,要么存在其他问题,限制了它们在实际应用中的效用。当ICER很大且真实效果差异相对于其标准误差较小时,这些问题最为突出。对百分位数自助置信区间进行修改,涉及对样本空间重新排序,可部分解决该问题。

相似文献

1
Problems with interval estimates of the incremental cost-effectiveness ratio.增量成本效果比的区间估计问题。
Med Decis Making. 1999 Jan-Mar;19(1):9-15. doi: 10.1177/0272989X9901900102.
2
Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.通过自助法提升成本效益分析:一种用于置信区间估计的非参数方法。
Health Econ. 1997 Jul-Aug;6(4):327-40. doi: 10.1002/(sici)1099-1050(199707)6:4<327::aid-hec282>3.0.co;2-w.
3
Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals.增量成本效益比的不确定性。Fieller置信区间与自助法置信区间的比较。
Int J Technol Assess Health Care. 1999 Summer;15(3):608-14.
4
Nonparametric statistical methods for cost-effectiveness analyses.用于成本效益分析的非参数统计方法。
Biometrics. 2006 Jun;62(2):576-88. doi: 10.1111/j.1541-0420.2006.00509.x.
5
A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored.
Med Decis Making. 2002 Mar-Apr;22(2):173-7. doi: 10.1177/0272989X0202200214.
6
A study on confidence intervals for incremental cost-effectiveness ratios.增量成本效益比置信区间的研究
Biom J. 2008 Aug;50(4):505-14. doi: 10.1002/bimj.200810439.
7
Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.非参数法在成本效益分析中的应用:中心极限定理与自助法的比较。
Health Econ. 2010 Mar;19(3):316-33. doi: 10.1002/hec.1477.
8
Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.随机成本效益分析中的估计、效能和样本量计算。
Pharmacoeconomics. 2007;25(6):455-66. doi: 10.2165/00019053-200725060-00002.
9
Average cost-effectiveness ratio with censored data.含截尾数据的平均成本效益比。
J Biopharm Stat. 2012;22(2):401-15. doi: 10.1080/10543406.2010.544437.
10
[Non-parametric methods for estimating confidence intervals around the incremental cost-effectiveness ratio].
Epidemiol Prev. 2008 Nov-Dec;32(6):307-13.

引用本文的文献

1
Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.净收益分离和决策曲线:成本效益估计的概率框架。
Stat Methods Med Res. 2021 May;30(5):1306-1319. doi: 10.1177/0962280221995972. Epub 2021 Apr 7.
2
Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders.从带有测量和未测量混杂因素的理赔和登记数据中估计成本效益。
Stat Methods Med Res. 2019 Jul;28(7):2227-2242. doi: 10.1177/0962280218759137. Epub 2018 Feb 22.
3
Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.
成本效益分析:统计分析中新报告标准的一项提议。
J Biopharm Stat. 2014;24(2):443-60. doi: 10.1080/10543406.2013.860157.
4
Median-Based Incremental Cost-Effectiveness Ratio (ICER).基于中位数的增量成本效益比(ICER)。
J Stat Theory Pract. 2012;6(3):428-442. doi: 10.1080/15598608.2012.695571. Epub 2012 Aug 10.
5
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.基层医疗中哮喘管理使用皮质类固醇吸入器装置的成本效益分析:一项真实世界观察性研究。
Clinicoecon Outcomes Res. 2010;2:75-85. doi: 10.2147/ceor.s10835. Epub 2010 Jul 1.
6
Management of common bile duct stones in cirrhotic patients with coagulopathy: a comparison of supra-papillary puncture and standard cannulation technique.肝硬化伴凝血功能障碍患者胆总管结石的处理:经乳头上方穿刺与标准置管技术的比较。
Dig Dis Sci. 2011 Jun;56(6):1904-11. doi: 10.1007/s10620-011-1593-2. Epub 2011 Feb 12.
7
Assessing technological change in cardiothoracic surgery.评估心胸外科的技术变革。
Semin Thorac Cardiovasc Surg. 2009 Spring;21(1):28-34. doi: 10.1053/j.semtcvs.2009.05.001.
8
Cost-effectiveness of palliation of unresectable esophageal cancer.无法切除的食管癌姑息治疗的成本效益
Dig Dis Sci. 2008 Dec;53(12):3103-11. doi: 10.1007/s10620-008-0302-2. Epub 2008 Jun 4.
9
Joint distribution approaches to simultaneously quantifying benefit and risk.用于同时量化获益和风险的联合分布方法。
BMC Med Res Methodol. 2006 Oct 12;6:48. doi: 10.1186/1471-2288-6-48.
10
Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.使用和解读成本效益可接受性曲线:以房颤管理策略试验数据为例
BMC Health Serv Res. 2006 Apr 19;6:52. doi: 10.1186/1472-6963-6-52.